Oppenheimer lowered the firm’s price target on BridgeBio Oncology (BBOT) to $22 from $23 and keeps an Outperform rating on the shares after its wider than expected loss. The firm has also updated its operating expense estimates based on guidance from management, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBOT:
- BridgeBio Oncology reports Q3 EPS ($1.03), consensus (34c)
- BridgeBio Oncology’s Promising Preclinical Data and Strategic Advancements Justify Buy Rating
- BridgeBio Oncology announces new preclinical data on BBO-11818 study
- BridgeBio Oncology management to meet with Oppenheimer
- BridgeBio Oncology initiated with an Outperform at Leerink